A review of Lassa fever vaccine candidates

Lassa fever is a zoonotic disease caused by the Lassa virus, a rodent-borne arenavirus endemic to West Africa. Recent steady increase in reported cases of the disease in Nigeria, where 123 deaths occurred in 546 confirmed cases in 2019 has further underlined the need to accelerate the development of...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in virology 2019-08, Vol.37, p.105-111
Main Authors: Salami, Kolawole, Gouglas, Dimitrios, Schmaljohn, Connie, Saville, Melanie, Tornieporth, Nadia
Format: Article
Language:English
Subjects:
Animals
Antigens, Viral - immunology
Clinical Trials as Topic
Disease Models, Animal
Humans
Lassa Fever - prevention & control
Lassa virus - genetics
Lassa virus - immunology
Rodentia
Viral Vaccines - classification
Viral Vaccines - genetics
Viral Vaccines - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lassa fever is a zoonotic disease caused by the Lassa virus, a rodent-borne arenavirus endemic to West Africa. Recent steady increase in reported cases of the disease in Nigeria, where 123 deaths occurred in 546 confirmed cases in 2019 has further underlined the need to accelerate the development of vaccines for preventing the disease. Intensified research and development of Lassa fever medical countermeasures have yielded some vaccine candidates with preclinical scientific plausibility using predominantly novel technology. The more advanced candidates are based on recombinant measles, Vesicular Stomatitis Virus or Mopiea and Lassa virus reassortants expressing Lassa virus antigens, and the deoxyribonucleic acid platform. However, the Lassa fever portfolio still lags behind other neglected tropical diseases’, and further investments are needed for continued development and additional research, such as the safety and efficacy of these vaccine candidates in special populations.
ISSN:1879-6257
1879-6265
DOI:10.1016/j.coviro.2019.07.006